Complete response after treatment with first-line targeted anti-vascular endothelial growth factor therapy in metastatic renal cancer: what next?

被引：1
|
作者：
Zaffuto, Emanuele [1 ,2 ]
Karakiewicz, Pierre I. [2 ]
Capitanio, Umberto [1 ]
机构：
[1] IRCCS Osped San Raffaele, Urol Res Inst, Unit Urol, Div Oncol, Milan, Italy
[2] Univ Montreal, Ctr Hlth, Canc Prognost & Hlth Outcomes Unit, Montreal, PQ, Canada
来源：
ANNALS OF TRANSLATIONAL MEDICINE | 2016年 / 4卷 / 15期
关键词：
CELL CARCINOMA; INTERFERON ALPHA-2A; SURVIVAL; INTERLEUKIN-2; SORAFENIB; AGENTS;
D O I：
10.21037/atm.2016.06.25
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Doublet regimen plus anti-vascular endothelial growth factor drug regimen after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer
    Matsumoto, T.
    Ikoma, T.
    Nagai, H.
    Watanabe, T.
    Yasui, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S148 - S149
  • [2] Efficacy and safety of anti-vascular endothelial growth factor therapies in older patients for first line treatment of metastatic renal cell carcinoma
    Dupuis, Hugo Georges Arthur
    Chebbi, Ala
    Surlemont, Louis
    Rigal, Olivier
    Di Fiore, Frederic
    Pfister, Christian
    Nouhaud, Francois-Xavier
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2021, 10 (06) : 2418 - 2426
  • [3] Anti-epidermal or anti-vascular endothelial growth factor as first-line metastatic colorectal cancer in modified Glasgow prognostic score 2′ patients
    Dreanic, Johann
    Dhooge, Marion
    Barret, Maximilien
    Brezault, Catherine
    Mir, Olivier
    Chaussade, Stanislas
    Coriat, Romain
    JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2015, 6 (03) : 231 - 236
  • [4] Efficacy and safety of anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy for metastatic colorectal cancer in first-line and second-line therapies: a meta-analysis
    Wang, Hongchi
    Ma, Bin
    Gao, Peng
    Song, Yongxi
    Xu, Qingzhou
    Hu, Yaoyuan
    Zhang, Cong
    Wang, Zhenning
    ONCOTARGETS AND THERAPY, 2016, 9 : 5405 - 5416
  • [5] Anti-Vascular Endothelial Growth Factor Therapy in Breast Cancer
    Kristensen, Tina Bogelund
    Knutsson, Malin L. T.
    Wehland, Markus
    Laursen, Britt Elmedal
    Grimm, Daniela
    Warnke, Elisabeth
    Magnusson, Nils E.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2014, 15 (12) : 23024 - 23041
  • [6] A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
    Yang, JC
    Haworth, L
    Sherry, RM
    Hwu, P
    Schwartzentruber, DJ
    Topalian, SL
    Steinberg, SM
    Chen, HX
    Rosenberg, SA
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (05): : 427 - 434
  • [7] Anti-Vascular Endothelial Growth Factor Therapy and Renal Thrombotic Microangiopathy
    Sorenson, Christine M.
    Sheibani, Nader
    ARCHIVES OF OPHTHALMOLOGY, 2011, 129 (08) : 1082 - 1082
  • [8] Response to First Intravitreal Anti-Vascular Endothelial Growth Factor Injection
    Saurabh, Kumar
    OPHTHALMOLOGICA, 2016, 236 : 48 - 48
  • [9] Renal damage associated with anti-vascular endothelial growth factor treatment
    Panigrahi, Pradeep K.
    Satapathy, Jasmita
    Minj, Anita
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2024, 72 (04) : 608 - 609
  • [10] A prospective observational study on the evaluation of everolimus-related adverse events in metastatic renal cell carcinoma after first-line anti-vascular endothelial growth factor therapy: the AFINITE study in France
    Florence Joly
    Jean-Christophe Eymard
    Laurence Albiges
    Thierry Nguyen
    Aline Guillot
    Frederic Rolland
    Dominique Spaeth
    Brigitte Laguerre
    Thierry Lebret
    Nadia Kelkouli
    Khemaies Slimane
    Alain Ravaud
    Supportive Care in Cancer, 2017, 25 : 2055 - 2062
12345